ScienceDex / Researcher record
Durbin, Anna Palmer
- Johns Hopkins University · Public Health (NIH department code)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
- Top 10% Funded
- Early Career
NIH Funding · FY2023
Award data coverage
One fiscal year is available for this record. This does not establish the first NIH award or current employer.
Single fiscal year on record (FY2023): $3.1M in linked award amounts across 1 award record · Award-linked rank #1733.
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY2023 · selected1 record
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Publications
Loading publications…
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2023 onlyCareer claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2027.
FY2023 award categories
- Public Health
FY2023 award records by amount
NIH award records listing Durbin, Anna Palmer as a PI. Multi-PI records show the full award amount for context.
- 75N93019D00031-0-759302300004-1N01Contact PIA STUDY TO ASSESS EFFICACY, SAFTETY AND PHARMACOKINETICS OF EYU688 IN HEALTHY PARTICIPANTS CHALLENGED WITH DENGUE SEROTYPE 2Johns Hopkins University · Public Health (NIH department code)$3.1Maward amount
Award organization
Organizations that administered FY2023 awards listing Durbin, Anna Palmer as a PI.
FY2023 award administered by Johns Hopkins University (MD).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2023First NIH AwardJohns Hopkins University
- 2023$500K Cumulative Funding
- 2023$1M Cumulative Funding
- 2023$2M Cumulative Funding
- 2023Entered Top 50% NationallyRanked #1733
- 2023Entered Top 25% NationallyRanked #1733
- 2023Entered Top 10% NationallyRanked #1733